{"transactions":[{"id":730070,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003042","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514826003042/form4.xml","form_type":"4"}},{"id":739303,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:15:19.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":77000,"derivative":{"exercise_price":1.22,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001570392-26-000003","document":"form4-06122026_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000157039226000003/form4-06122026_040614.xml","form_type":"4"}},{"id":769613,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:36:35.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002563","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514826002563/form4.xml","form_type":"4"}},{"id":1107551,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:57:11.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002174","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514825002174/form4.xml","form_type":"4"}},{"id":1112964,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:19:05.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.75,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-25-016934","document":"form4-06122025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925016934/form4-06122025_040614.xml","form_type":"4"}},{"id":1419770,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-29T20:15:12.000Z","date":"2024-08-28","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.45,"expiration_date":"2034-08-28","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-022535","document":"form4-08292024_040808.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588924022535/form4-08292024_040808.xml","form_type":"4"}},{"id":1470381,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T21:28:15.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":6.52,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-24-001777","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514824001777/form4.xml","form_type":"4"}},{"id":1860148,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:22:35.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.86,"expiration_date":"2033-06-07","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-035843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919123035843/doc4.xml","form_type":"4"}},{"id":2114085,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T00:25:32.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":35235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 36 equal monthly installments beginning on October 12, 2022 (\"Vesting Commencement Date\"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":35235,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":35235},"source":{"system":"sec-edgar","filing":"0001209191-22-057401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000120919122057401/doc4.xml","form_type":"4"}},{"id":2133395,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-10-21T23:01:16.000Z","date":"2022-10-19","kind":"purchase","acquired":true,"shares":15000,"price":5.32,"value":79800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within a one dollar range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-22-054325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919122054325/doc4.xml","form_type":"4"}},{"id":2187863,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-11T22:03:23.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested\non the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each\nsuch vesting date."}],"balance_after":30000,"derivative":{"exercise_price":6.07,"expiration_date":"2032-07-05","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-045474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919122045474/doc4.xml","form_type":"4"}},{"id":2608510,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T00:00:31.000Z","date":"2021-03-11","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month."}],"balance_after":131000,"derivative":{"exercise_price":17.75,"expiration_date":"2027-11-21","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-050719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121050719/doc4.xml","form_type":"4"}},{"id":2608509,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-08-11T00:00:31.000Z","date":"2021-08-06","kind":"sale","acquired":false,"shares":5989,"price":139.46,"value":835225.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":1891,"source":{"system":"sec-edgar","filing":"0001209191-21-050719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121050719/doc4.xml","form_type":"4"}},{"id":2608508,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-08-11T00:00:31.000Z","date":"2021-08-06","kind":"sale","acquired":false,"shares":19011,"price":138.22,"value":2627700.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":7880,"source":{"system":"sec-edgar","filing":"0001209191-21-050719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121050719/doc4.xml","form_type":"4"}},{"id":2608507,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-08-11T00:00:31.000Z","date":"2021-08-06","kind":"exercise","acquired":true,"shares":25000,"price":17.75,"value":443750.0,"ownership":{"direct":true},"balance_after":26891,"source":{"system":"sec-edgar","filing":"0001209191-21-050719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121050719/doc4.xml","form_type":"4"}},{"id":2621962,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-29T21:39:46.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":5.54,"expiration_date":"2031-06-14","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-048573","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919121048573/doc4.xml","form_type":"4"}},{"id":2792108,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-12T22:50:51.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025."}],"balance_after":9000,"derivative":{"underlying":"Common Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-020263","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121020263/doc4.xml","form_type":"4"}},{"id":2792107,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-12T22:50:51.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":25360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 11, 2021 with respect to 25,360 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021."}],"balance_after":25360,"derivative":{"exercise_price":133.88,"expiration_date":"2031-03-11","underlying":"Common Shares","underlying_shares":25360},"source":{"system":"sec-edgar","filing":"0001209191-21-020263","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121020263/doc4.xml","form_type":"4"}},{"id":2792106,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-03-12T22:50:51.000Z","date":"2021-03-10","kind":"tax_withholding","acquired":false,"shares":1352,"price":124.15,"value":167850.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person."}],"balance_after":1891,"source":{"system":"sec-edgar","filing":"0001209191-21-020263","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121020263/doc4.xml","form_type":"4"}},{"id":2792105,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-03-12T22:50:51.000Z","date":"2021-03-10","kind":"exercise","acquired":true,"shares":2833,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."}],"balance_after":3243,"source":{"system":"sec-edgar","filing":"0001209191-21-020263","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919121020263/doc4.xml","form_type":"4"}},{"id":3011680,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-06T21:48:24.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":11666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on October 5, 2020 with respect to 11,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020."}],"balance_after":11666,"derivative":{"exercise_price":86.75,"expiration_date":"2030-10-05","underlying":"Common Shares","underlying_shares":11666},"source":{"system":"sec-edgar","filing":"0001209191-20-054070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120054070/doc4.xml","form_type":"4"}},{"id":3039360,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-03T20:46:44.000Z","date":"2020-09-01","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month."}],"balance_after":156000,"derivative":{"exercise_price":17.75,"expiration_date":"2027-11-21","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-049430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120049430/doc4.xml","form_type":"4"}},{"id":3039359,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-09-03T20:46:44.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":2800,"price":93.18,"value":260904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.74, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":410,"source":{"system":"sec-edgar","filing":"0001209191-20-049430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120049430/doc4.xml","form_type":"4"}},{"id":3039358,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-09-03T20:46:44.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":6400,"price":92.23,"value":590272.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.80 to $92.72, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":3210,"source":{"system":"sec-edgar","filing":"0001209191-20-049430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120049430/doc4.xml","form_type":"4"}},{"id":3039357,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-09-03T20:46:44.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":2800,"price":91.39,"value":255892.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.78 to $91.76, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":9610,"source":{"system":"sec-edgar","filing":"0001209191-20-049430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120049430/doc4.xml","form_type":"4"}},{"id":3039356,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-09-03T20:46:44.000Z","date":"2020-09-01","kind":"exercise","acquired":true,"shares":12000,"price":17.75,"value":213000.0,"ownership":{"direct":true},"balance_after":12410,"source":{"system":"sec-edgar","filing":"0001209191-20-049430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120049430/doc4.xml","form_type":"4"}},{"id":3067539,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-05T20:20:37.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month."}],"balance_after":168000,"derivative":{"exercise_price":17.75,"expiration_date":"2027-11-21","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-045100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120045100/doc4.xml","form_type":"4"}},{"id":3067538,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-08-05T20:20:37.000Z","date":"2020-08-03","kind":"sale","acquired":false,"shares":5448,"price":87.333,"value":475790.184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.875 to $87.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":410,"source":{"system":"sec-edgar","filing":"0001209191-20-045100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120045100/doc4.xml","form_type":"4"}},{"id":3067537,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-08-05T20:20:37.000Z","date":"2020-08-03","kind":"sale","acquired":false,"shares":6552,"price":86.2528,"value":565128.3456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.78 to $86.77, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":5858,"source":{"system":"sec-edgar","filing":"0001209191-20-045100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120045100/doc4.xml","form_type":"4"}},{"id":3067536,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2020-08-05T20:20:37.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":12000,"price":17.75,"value":213000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 410 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan."}],"balance_after":12410,"source":{"system":"sec-edgar","filing":"0001209191-20-045100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120045100/doc4.xml","form_type":"4"}},{"id":3118198,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T23:08:53.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.74,"expiration_date":"2030-06-05","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-035119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000120919120035119/doc4.xml","form_type":"4"}},{"id":3213599,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-12T20:30:15.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023."}],"balance_after":8500,"derivative":{"underlying":"Common Shares","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-20-018513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120018513/doc4.xml","form_type":"4"}},{"id":3213598,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-12T20:30:15.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020."}],"balance_after":35000,"derivative":{"exercise_price":44.67,"expiration_date":"2030-03-10","underlying":"Common Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-018513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919120018513/doc4.xml","form_type":"4"}},{"id":3350941,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-05T21:05:14.000Z","date":"2019-12-03","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest as follows:  two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest as follows:  two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022."}],"balance_after":20000,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-059280","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000120919119059280/doc4.xml","form_type":"4"}},{"id":3606351,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-07T21:14:13.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019."}],"balance_after":75000,"derivative":{"exercise_price":40.87,"expiration_date":"2029-03-05","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-006653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924319006653/doc4.xml","form_type":"4"}},{"id":3892656,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-16T01:37:28.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":20760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2018 with respect to 20,760 Common Shares with 100% of the shares vesting in 48 equal monthly installments."}],"balance_after":20760,"derivative":{"exercise_price":59.31,"expiration_date":"2028-06-15","underlying":"Common Shares","underlying_shares":20760},"source":{"system":"sec-edgar","filing":"0000899243-18-016872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318016872/doc4.xml","form_type":"4"}},{"id":4003490,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-09T21:50:16.000Z","date":"2018-03-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments."}],"balance_after":25000,"derivative":{"exercise_price":51.49,"expiration_date":"2028-03-07","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-006954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318006954/doc4.xml","form_type":"4"}},{"id":4163743,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-14T22:19:22.000Z","date":"2017-11-13","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on November 13, 2017, 25% of the shares shall vest on November 13, 2018 and the remaining shares shall vest in 36 equal monthly installments on the first day of each succeeding calendar month."}],"balance_after":180000,"derivative":{"exercise_price":17.75,"expiration_date":"2027-11-21","underlying":"Common Shares","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000899243-17-026210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924317026210/doc4.xml","form_type":"4"}},{"id":4255752,"issuer":{"id":121309,"kind":"organization","name":"ABIOMED INC","symbol":"NASD"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, CFO"}}],"security":"Common Stock, $.01 par value","published_at":"2017-07-18T16:23:24.000Z","date":"2017-07-15","kind":"tax_withholding","acquired":false,"shares":3925,"price":145.07,"value":569399.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F5","text":"Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units."}],"balance_after":27081,"source":{"system":"sec-edgar","filing":"0001179110-17-010419","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/815094/000117911017010419/edgar.xml","form_type":"4"}},{"id":4304043,"issuer":{"id":121309,"kind":"organization","name":"ABIOMED INC","symbol":"NASD"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, CFO"}}],"security":"Common Stock, $.01 par value","published_at":"2017-05-26T16:08:24.000Z","date":"2017-05-24","kind":"tax_withholding","acquired":false,"shares":1567,"price":134.74,"value":211137.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F5","text":"Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units."}],"balance_after":34931,"source":{"system":"sec-edgar","filing":"0001179110-17-008077","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/815094/000117911017008077/edgar.xml","form_type":"4"}},{"id":4317009,"issuer":{"id":121309,"kind":"organization","name":"ABIOMED INC","symbol":"NASD"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, CFO"}}],"security":"Stock option (right to buy)","published_at":"2017-05-17T16:50:49.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6."}],"balance_after":6000,"derivative":{"exercise_price":134.51,"exercise_date":"2018-05-15","expiration_date":"2027-05-15","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-17-007419","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/815094/000117911017007419/edgar.xml","form_type":"4"}},{"id":4317008,"issuer":{"id":121309,"kind":"organization","name":"ABIOMED INC","symbol":"NASD"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, CFO"}}],"security":"Common Stock, $.01 par value","published_at":"2017-05-17T16:50:49.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates."}],"balance_after":36498,"source":{"system":"sec-edgar","filing":"0001179110-17-007419","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/815094/000117911017007419/edgar.xml","form_type":"4"}},{"id":4317007,"issuer":{"id":121309,"kind":"organization","name":"ABIOMED INC","symbol":"NASD"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, CFO"}}],"security":"Common Stock, $.01 par value","published_at":"2017-05-17T16:50:49.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":8198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates."}],"balance_after":34998,"source":{"system":"sec-edgar","filing":"0001179110-17-007419","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/815094/000117911017007419/edgar.xml","form_type":"4"}}]}